Tag: Portola Pharmaceuticals Inc (PTLA)

We call it the bad market

We call it the bad market

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of the interest rate does not and should not mean a demise of the companies trading on the NASDAQ and other stock exchanges. The biotech group of firms with strong scientific fundamentals will not stop innovating and bringing breakthroughs to millions of people who are desperate for them if an …
Why Portola’s stock decline

Why Portola’s stock decline

Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed to put two FDA-approved products on the market. They are: Bevyxxa® (betrixaban): The first and only once-daily oral Factor Xa inhibitor, for the prevention of deep vein thrombosis (DVT), that subject them to venous thromboembolism (VTE), which could have life-threatening lung embolism. Andexxa®: The first and only antidote for patients treated with rivaroxaban and apixaban when reversal …
About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

Portola Pharmaceuticals Appoints Scott Garland as President and Chief Executive Officer, Effective October 8, 2018. Portola (PTLA) appointed a new president, Mr. Scott Garland, who was Relypsa’s president and previously chief commercial officer and responsible for the integration and growth of the U.S. operations after Relypsa was acquired by Vifor Pharma Group in 2016. Prior to Relypsa, Mr. Garland was executive vice president and chief commercial officer of Exelixis, Inc., …
Outperforming, favorite, and undervalued biotech firms

Outperforming, favorite, and undervalued biotech firms

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid scientific fundamentals, superior scientists and advanced technologies is what motivates us to pick for investment biotech and biopharmaceutical firms. So, let’s see what has been approved in the parting week  from firms that we picked for investment.       IMPORTANT APPROVALS       Prohost Picked Firm     …
About Portola

About Portola

Portola (PTLA) has two important approved breakthrough products and an investigational product having promising results on very difficult-to-treat cancers. Instead of soaring following the approval of its two drugs and the good results coming from the investigational third drug, Portola’s stock took several dives, which raised the eyebrows of many investors and motivated more shareholders to sell PTLA. Let us see whether the firm deserves …
When all the prophets are taken by surprise

When all the prophets are taken by surprise

When the Goal is Reaching into the Future, Pessimists Have No Place on the Ship The revolution in the biotech sector has proven to be moving fast towards reaching goals that were impossible to imagine a couple of years ago that they could be attainable. This is not true only regarding lay investors, or desperate patients, but also regarding the most professional clinicians, researchers and …
Why Portola couldn’t flex its muscles or use them yet

Why Portola couldn’t flex its muscles or use them yet

All the buying and selling of Portola (PTLA) will not make any sense to us until the firm fulfills its obligations towards what is required by the authorities, by health care and by private third-party payers.  So, in the reporting of its Q2 financial results for the three months ending June 30, 2018, in addition to providing a corporate update, nothing matters really except knowing where the …
The FDA Approves Portola Pharmaceuticals’ Andexxa®. The First and ONLY Antidote for the Reversal of Factor Xa Inhibitors

The FDA Approves Portola Pharmaceuticals’ Andexxa®. The First and ONLY Antidote for the Reversal of Factor Xa Inhibitors

The U.S. Food and Drug Administration (FDA) has approved Portola’s (PTLA) drug Andexxa®, the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Commenting on the approval, Stuart J. Connolly, M.D., ANNEXA-4 Executive Committee chairman and professor in the Department of Medicine of the Faculty of Health Sciences at McMaster University in Hamilton, Ontario said, “Today’s approval represents …
Observing Queer Stories

Observing Queer Stories

Prohost Letter #418 Observing Queer Stories  PORTOLA - Portola (PTLA) has been granted approval of an important factor Xa inhibitor Bevyxxa (betrixa-­ban for extended prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for a life-­threatening VTE . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

Portola Pharmaceuticals and the CHMP’s Oral Explanations for Andexanet Alfa and Betrixaban Portola (PTLA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated a positive trend vote on the Marketing Authorization Application (MAA) for Portola’s factor Xa inhibitor antidote andexanet alfa. The agency has also communicated a negative trend vote for betrixaban, the firm’s oral, Factor Xa inhibitor. Andexanet Alfa Bill Lis, the chief executive officer …
The Year in Review Part 1

The Year in Review Part 1

Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN AWESOME YEAR for the biotech sector regarding its accomplishments. Many of the accomplished programs were unheard of regarding the degree of their positive impact on medical practice. Unfortunately, many of these accomplishments, which included the making of new discoveries, the creation of novel advanced technologies and the design of …
Portola: The FDA Approves Bevyxxa

Portola: The FDA Approves Bevyxxa

After years of spending efforts in creating and developing its pipeline products, Portola (PTLA) has just been granted a U.S. Food and Drug Administration’s (FDA) approval of its Prior Approval Supplement (PAS) for the anticoagulant product Bevyxxa® (betrixaban). The product is approved ahead of its scheduled January 30th action date, which enables the release and distribution of its product inventory. Bevyxxa® is a factor Xa inhibitor approved on June 23, 2017 as a single-drug regimen for …
In Spite of Negative Indirect Attempts to Downgrade Portola, It Remains One of Our Favorites

In Spite of Negative Indirect Attempts to Downgrade Portola, It Remains One of Our Favorites

On Nov. 21, 2017, Portola Pharmaceuticals (PTLA) announced that the U.S. Food and Drug Administration (FDA) has informed it that it will respond to the Prior Approval Supplement (PAS) request to change the current manufacturing release specification within the standard 60-day extension period. No additional information was requested at this time. The new action date is January 30, 2018. Bill Lis, chief executive officer of Portola said, “As …
About Portola’s Conference Call Today

About Portola’s Conference Call Today

Portola Portola Pharmaceuticals (PTLA) announced that it will host a webcast and conference call to provide an update on its anticoagulant Factor Xa inhibitor Bevyxxa® (betrixaban) launch plans, the validation of the commercial manufacturing process and drug release timing. Conference Call Details: The live conference call will be held today, Tuesday, September 5, 2017, at 4:30 p.m. Eastern Time (1:30 p.m. PT). It can be accessed by …
Why Our Increased Enthusiasm for Incyte’s Product Baricitinib

Why Our Increased Enthusiasm for Incyte’s Product Baricitinib

Eli Lilly and Company (LLY) and Incyte (INCY) announced that, after discussions with the U.S. Food and Drug Administration (FDA) in late August, Lilly will resubmit the New Drug Application (NDA) for baricitinib before the end of January 2018. That was fast, we mean the re-submission. To remind you, the firms had submitted Baricitinib for review seeking marketing approval for rheumatoid arthritis in the U.S., the …
Some Good and Bad Stories

Some Good and Bad Stories

The Week in Review #2 The Fairest Upgrades of the Week - Some analysts gave a generous and well measured dose of fairness evaluating biotech firms’ accomplishments. Credit Swiss upgrades Portola Pharmaceuticals (PTLA) from neutral to outperform while maintaining its $70 target . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Stocks’ Declines That Offer Real Opportunities for Accumulation at Bargain Prices

Stocks’ Declines That Offer Real Opportunities for Accumulation at Bargain Prices

AFTER MANY OF THE PROHOST PICKED STOCKS NEARED REACHING THE PROHOST NEAR-TERM TARGETS, recently, external circumstances and exaggerated delaying news, some of our rallied stocks gave back some of their gains. Two reasons were behind the decline in some precious picked stocks, which occurred one after the other in a very short period of time. The first reason for the declines came through traders’ practice …
Prohost Letter #412 Part 1

Prohost Letter #412 Part 1

Prohost Letter #412 Part 1 Updating Our Targets - This Letter will be of three parts. The first part (today’s  issue)aims at presenting our adjusted targets based on current news and updates related to the Prohost picks. A Case in Point - PORTOLA - For example, Portola (PTLA) has recently been granted FDA approval for its Factor 10 (FX) inhibitor anticoagulant drug Bevyxxa (betrixaban . …
Portola’s Next Moves and Its Upcoming Approval

Portola’s Next Moves and Its Upcoming Approval

The most important last barrier to cross or dismantle for drug developers is the approval of novel products that amplify the improvement of previous drugs. The approvals of drugs in the U.S. and Europe open the door for the same drugs to be approved and marketed in the rest of the world. For the revenue-generating firms, each and every approval helps grow their revenues. With …